Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test. by Temfack, E et al.
fmicb-09-00409 March 13, 2018 Time: 11:37 # 1
ORIGINAL RESEARCH
published: 13 March 2018
doi: 10.3389/fmicb.2018.00409
Edited by:
Frederic Lamoth,
Centre Hospitalier Universitaire
Vaudois (CHUV), Switzerland
Reviewed by:
Jesus Guinea,
Hospital Gregorio Marañón, Spain
Martin Hoenigl,
University of California, San Diego,
United States
*Correspondence:
Olivier Lortholary
olivier.lortholary@wanadoo.fr
Elvis Temfack
temfack@doctor.com
†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 27 September 2017
Accepted: 21 February 2018
Published: 13 March 2018
Citation:
Temfack E, Kouanfack C,
Mossiang L, Loyse A, Fonkoua MC,
Molloy SF, Koulla-Shiro S,
Delaporte E, Dromer F, Harrison T
and Lortholary O (2018) Cryptococcal
Antigen Screening in Asymptomatic
HIV-Infected Antiretroviral Naïve
Patients in Cameroon and Evaluation
of the New Semi-Quantitative
Biosynex CryptoPS Test.
Front. Microbiol. 9:409.
doi: 10.3389/fmicb.2018.00409
Cryptococcal Antigen Screening
in Asymptomatic HIV-Infected
Antiretroviral Naïve Patients in
Cameroon and Evaluation of the
New Semi-Quantitative Biosynex
CryptoPS Test
Elvis Temfack1,2* , Charles Kouanfack3, Leonella Mossiang3, Angela Loyse4,
Marie C. Fonkoua5, Síle F. Molloy4, Sinata Koulla-Shiro3,6, Eric Delaporte6,7,
Françoise Dromer1†, Thomas Harrison4† and Olivier Lortholary1,8*
1 Institut Pasteur, Centre National de la Recherche Scientifique, Unité de Mycologie Moléculaire, UMR 2000, Paris, France,
2 Department of Internal Medicine, Douala General Hospital, Douala, Cameroon, 3 Day Hospital, Yaoundé Central Hospital,
Yaoundé, Cameroon, 4 Centre for Global Health, Institute for Infection and Immunity, St George’s, University of London,
London, United Kingdom, 5 Microbiology Unit, Centre Pasteur du Cameroun, Yaoundé, Cameroon, 6 Cameroon Site, French
National Agency for Research on AIDS and Viral Hepatitis, Yaounde, Cameroun, 7 INSERM U1175-IRD UMI 233, University
of Montpellier, Montpellier, France, 8 Infectious Diseases and Tropical Medicine Department, Necker Pasteur Infectious
Diseases Centre, Necker-Enfants Malades Hospital, APHP, Institut Hospitalo-Universitaire Imagine, Paris Descartes
University, Paris, France
Background: Cryptococcal meningitis (CM) is a major cause of AIDS-related mortality
in Africa. Detection of serum cryptococcal antigen (CrAg) predicts development of
CM in antiretroviral (ART) naïve HIV-infected patients with severe immune depression.
Systematic pre-ART CrAg screening and pre-emptive oral fluconazole is thus
recommended. We postulated that a semi-quantitative CrAg screening approach could
offer clinically relevant advantages.
Methods: ART-naïve asymptomatic adult outpatients with <100 CD4 cells/mm3
presenting to the Yaoundé Central Hospital, Cameroon were screened for CrAg using
the IMMY lateral flow assay (LFA). CrAg positive patients were consented for lumbar
puncture and those with proven CM were treated with combination antifungal therapy
and those with no CM were offered long-term oral fluconazole. Simultaneous on-
site evaluation of CrAg detection using the new LFA Biosynex R© CryptoPS test was
performed and both tests were subsequently compared to a reference commercialized
CrAg enzyme immunoassay (EIA).
Results: Prevalence of serum CrAg in 186 screened adults was 7.5% (95%CI: 4.5–
12.4). In CrAg positive patients, CM prevalence was 45.5% (95%CI: 18.3–75.7). IMMY
and Biosynex CryptoPS strongly agreed in serum, plasma, and cerebrospinal fluid
(Kappa: 98.4, 99.5, 100%, respectively, p < 0.001), and disagreed in urine (29 isolated
positive CrAg in urine with IMMY, none with Biosynex and none of whom had proven
CM). Compared to EIA, serum specificities were 96.6 and 98.3%, respectively. With
Biosynex CryptoPS, all CM patients were serum T2-band positive compared to none
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without CM. Median EIA reciprocal titre was 160 (IQR: 13.5–718.8) and titres >160
strongly correlated with proven CM and Biosynex CryptoPS T2-band positivity. During
the 1-year follow up period, there was no incident case of CM among screened patients
and overall incidence of all-cause mortality was 31.5 per 100 person-years-at-risk
(95%CI: 23.0–43.1).
Conclusion: HIV-associated asymptomatic cryptococcosis is common in Cameroon,
warranting integrated systematic screening and treatment. Biosynex CryptoPS holds
promise, at point of care, for rapidly stratifying CrAg positive patients for optimal
management including lumbar puncture and combination antifungal therapy when
needed.
Summary findings: Prevalence of CrAg and meningitis (CM) is high in Cameroon.
Biosynex CryptoPS is comparable to IMMY LFA in CrAg screening. Its T2-band
correlates with high antigen titres and CM, thus promising for identifying patients
requiring effective induction therapy.
Note: This study was presented in part at the 10th International Conference on
Cryptococcus and Cryptococcosis (ICCC) in Iguazu in Brazil from 26 to 30th March
2017 and won a prize oral presentation.
Keywords: cryptococcosis, cryptococcal antigen, screening, point of care, lateral flow assay
INTRODUCTION
Cryptococcal meningitis (CM) is a major cause of morbidity and
mortality among patients with advanced HIV infection especially
in resource limited settings. Cryptococcosis is responsible for
up to 15% of AIDS related mortality of which 75% is in Sub-
Saharan Africa (Rajasingham et al., 2017). Global estimates
suggest that CM represents the leading cause of adult meningitis
worldwide and the second cause of death after tuberculosis
(French et al., 2002; Liechty et al., 2007). Though existing
evidence of an association between antiretroviral therapy (ART)
program implementation and decreased CM incidence (Mirza
et al., 2003; Dromer et al., 2004), in spite of efforts to scale up
ART coverage, at least 20% of patients still present to ART care
with <100 CD4 cells/ml (Siedner et al., 2015). More so, in the
African setting (Rajasingham et al., 2017), in the latter patients
with detectable untreated blood cryptococcal antigen (CrAg),
about 25% subsequently develop CM within the first year of ART
compared to as few as no cases in CrAg negatives (Jarvis et al.,
2009).
In this setting, two strategies to reduce the incidence of
CM have been suggested. Universal fluconazole-based primary
prophylaxis, which resulted in decreased CM incidence, but had
no impact on overall mortality and thus not widely adopted
(Chang et al., 2005; Parkes-Ratanshi et al., 2011). The second
strategy consisted of pre-ART systematic screening for CrAg in
blood in profoundly immune depressed patients followed by pre-
emptive administration of fluconazole to CrAg positive patients
(Micol et al., 2007; Jarvis et al., 2012). The latter was endorsed by
2011 World Health Organization (WHO) rapid advice (World
Health Organization, 2011) which recommended screening
either with latex agglutination (LA) test or the Food and
Drug Administration (FDA)-approved lateral flow assay (LFA)
point of care (POC) immunochromatographic test (IMMY R©
diagnostics, Norman, OK, United States) (Rajasingham et al.,
2012; IMMY, 2017). This approach which has shown survival
benefits when coupled with enhanced adherence to ART (Meya
et al., 2010; Letang et al., 2015; Mfinanga et al., 2015; Rajasingham
et al., 2017), is cost-effective (Meya et al., 2010; Micol et al.,
2010; Jarvis et al., 2013; Smith et al., 2013) and has been
incorporated into national guidelines of many countries in the
Southern part of Africa (Rajasingham et al., 2017). Nevertheless,
Central Africa lags in adopting this strategy. Consequently,
through this prospective cohort study in Cameroon, we aimed
to determine the prevalence of CrAg in blood and asymptomatic
CM in ambulatory ART-naïve adults presenting with <100
CD4 cells/ml using IMMY LFA and the incidence of CM
during first year of ART in the context of screening. A second
objective was to assess the performances of a recently developed
semi-quantitative immunochromatographic POC test (Biosynex
CryptoPS, BIOSYNEX R© diagnostics, Strasbourg, France), capable
of identifying participants with high CrAg titres, a surrogate of
prevalent CM. We ultimately compared the performances of both
POC tests to those of the commercialized enzyme immunoassay
(EIA), the Premier R© CrAg (Meridian Bioscience, Inc., Newtown,
OH, United States), considered in here as the reference standard.
MATERIALS AND METHODS
Study Setting
This study was carried out at the Day Hospital of the Yaoundé
Central Hospital in Cameroon where the French National Agency
for Research on AIDS and Viral Hepatitis (ANRS) center is
located. This Day Hospital is a major HIV treatment center which
follows up over 9,000 patients presently on ART using updated
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national guidelines following WHO recommendations (World
Health Organization, 2016).
Study Procedure
This study was carried out in accordance with the
recommendations of the Cameroon National Ethics Committee
for Research in Human Health with written informed consent
from all included subjects. All subjects gave written informed
consent in accordance with the Declaration of Helsinki. The
protocol was approved by the Cameroon National Ethics
Committee for Research in Human Health and Administrative
Authorization for research was also obtained from the Cameroon
Ministry of Public Health. HIV-infected, ART naïve ambulatory
adults (>18 years) presenting with <100 CD4 cells/ml between
July 2015 and March 2017 with no history of cryptococcal
meningitis, were included. A standardized questionnaire was
used to anonymously record baseline sociodemographic data as
well as current symptoms at each visit.
On inclusion, participants were checked for symptoms
evocative of CM, and those with recent history of altered
mental status or febrile seizures were excluded. In the absence
of symptoms, specimens (blood and urine) were collected for
same day CrAg screening. CrAg screening was performed in
all patients on fresh serum and urine samples using the IMMY
LFA (IMMY, 2017) according to manufacturer’s procedure.
In addition, all samples were tested and interpreted using a
newly developed LFA-based immunochromatographic test called
Biosynex CryptoPS without prior knowledge of the results
obtained with the IMMY LFA test (Figure 1). Additionally,
plasma samples obtained on the same day as the serum and urine
were also screened with both POC.
Briefly, Biosynex CryptoPS can detect the four serotypes of
Cryptococcus spp., and provides results within 10 min. This test
has two bands: the T1-band is qualitative and the T2-band is
semi-quantitative. The T2 band will only appear in patients with
elevated CrAg titres (Sriruttan et al., 2016).
Patients were considered CrAg positive if serum samples were
positive using the IMMY LFA test but all patients with detectable
CrAg in any fluid were consented for lumbar puncture (LP).
Freshly obtained cerebrospinal fluid (CSF) was tested with both
POC. Direct examination was performed (Indian ink staining)
and CSF was cultured on Sabouraud dextrose. Participants with
laboratory proven CM (positive India ink and/or culture) were
offered treatment within the phase III “Advancing Cryptococcal
Meningitis Treatment in Africa” (ACTA) trial (Advancing
Cryptococcal Meningitis Treatment for Africa [ACTA], 2013).
Participants with detectable CrAg but no laboratory proven
CM were placed on pre-emptive oral fluconazole: 800 mg/day for
2 weeks, then 400 mg/day for 8 weeks and 200 mg/day from week
10 till two consecutive control CD4 cell counts at month 6 and
12 were both above 200 cells/ml (World Health Organization,
2011). CrAg negative participants were immediately started on
FIGURE 1 | Study procedure: identification, inclusion and screening of participants.
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ART without fluconazole, while those on fluconazole and those
treated for CM, had ART deferred by 2 and 4 weeks, respectively.
Follow up visits were every 2 weeks for the first 10 weeks,
then every 3 months for 1 year. At each visit, symptoms of
CM were carefully searched and if clinical suspicion, LP was
performed. ART adherence evaluation and support through
counseling and medication dispensation were also done. In case
of missed appointments, participants or closed family members
were followed-up by phone and verbal autopsies conducted for
participants who died.
To assess the performances of the LFA tests, we chose the EIA
Premier R© CrAg test (Meridian Bioscience, Inc., Newtown, OH,
United States) as reference standard. Aliquots of the 186 serum
samples stored at −80◦C at the Centre Pasteur du Cameroun
were subsequently transported frozen under rigorous conditions
to France for CrAg testing using EIA Premier R© according to
manufacturer’s procedure. For all EIA CrAg positive specimens,
CrAg titre determination was performed by EIA and with both
POC test (with Biosynex CryptoPS, both T1 and T2 titres were
determined). Results were expressed as reciprocal titre.
Statistical Analysis
Data were analyzed using STATA 13.0 software (StataCorp,
College Station, TX, United States). Results of CrAg screening
in the population were expressed as percentages (with their 95%
confidence interval [CI]). Categorical variables were compared
using Pearson’s Chi-square or Fischer’s exact test as required.
Continuous variables were reported as means (and standard
deviation [SD]) or median (and interquartile range [IQR])
as required. Student t-test or Wilcoxon rank sum test were,
respectively, used to compare means or medians as required.
Agreement between IMMY and Biosynex CryptoPS tests in
classifying study participants as positive or negative in each
specimen type with Indian ink staining or culture of CSF were
appraised using Kappa statistics and reported as percentages.
With reference to EIA, two-by-two tables were used to
estimate sensitivity and specificity of both POC and reported as
percentages with their 95%CI.
Cox proportional hazard ratios (HR) and Kaplan–Meier
curves were used to compare survival differences during the
first year following CrAg screening. In the multivariate analysis,
mortality-associated factors with p-value <0.1 in the univariate
analysis were included in the final model and reported as adjusted
hazard ratios (aHR) with their 95%CI. Evidence against the null
hypothesis was considered for a two-tailed p-value of <0.05.
RESULTS
Prevalence of Latent Cryptococcosis and
CM Based on Screening Using IMMY LFA
Between July 2015 and March 2017, 186 patients were screened
for CrAg. Mean age was 38.2 years (SD: 10.0) and 67.7%
(126/186) were women. Median body mass index was 21.0 kg/m2
(IQR: 18.8–23.2) and median CD4 T-cells was 44 cells/ml (IQR:
27–75) with no difference between those CrAg positive and
negative (Table 1).
TABLE 1 | Baseline characteristics of study population (n = 186) categorized by
serum cryptococcal antigen (CrAg) status using IMMY LFA.
Variables at baseline CrAg positive
(n = 14)
CrAg negative
(n = 172)
p-value
Socio-demographic
Age in years, mean (SD) 39.3 (10.5) 38.5 (10.2) 0.55
Male, n (%) 5 (35.7) 55 (32) 0.77
Clinical
History of tuberculosis,
n (%)
0 9 (5.3) 0.99
History of liver disease,
n (%)
0 5 (2.9) 0.99
Body mass index in
Kgm2, median (IQR)
20.6
(18.4–21.3)
21.0
(18.8–23.4)
0.36
Laboratory
CD4 cells/ml,
median (IQR)
44 (26–76) 48 (35–67) 0.48
Haemoglobin in g/dL,
median (IQR)
10.5 (9.6–11.3) 9.9 (8.9–11.3) 0.96
White blood
cells × 103/ml, median
(IQR)
2 (2.0–5.0) 1 (1–3) 0.05
Alanine transaminase in
IU/L, median (IQR)
32.4
(23.7–41.1)
27.6
(19.2–43.3)
0.96
Serum creatinine in
g/dL, median (IQR)
1 (0.9–1.2) 1 (0.8–1.2) 0.95
TABLE 2 | On site comparison of IMMY diagnostics lateral flow assay (LFA) and
Biosynex CryptoPS tests positivity in 186 fresh serum, plasma and urine samples,
and 23 cerebrospinal fluid (CSF) samples.
Specimen
types
IMMY LFA test
% (95% CI)
Biosynex
CryptoPS %
(95%CI)
%
agreement
(Kappa)
p-value
Serum
N = 186
7.5
(4.5–12.4)
5.9
(3.3–10.4)
98.4 0.001
Plasma
N = 186
6.5
(3.7–11.1)
5.9
(3.3–10.4)
99.5 0.001
Urine
N = 186
22.6
(17.1–29.2)
5.9
(3.3–10.4)
83.3 0.001
CSF
N = 23
17.4
(6.2–40.3)
17.4
(6.2–40.3)
100 0.001
Prevalence of serum CrAg was 7.5% (14/186) (Table 2).
Considering all screened specimens (serum/plasma, and urine),
23.1% (43/186) had detectable CrAg (Figure 2). Among the 43
patients with detectable CrAg in any site, 27 (62.8%) accepted a
LP including 11 of the 14 patients with positive serum CrAg. Four
of the 27 LPs did not yield CSF (4 patients with CrAg detection
positive in urine only) and 21/23 CSF (91.3%) were cultured (1
positive Indian ink CSF and one isolated urine CrAg were not
cultured).
Overall, CM was diagnosed in 21.7% (5/23) of patients by
means of a positive Indian ink staining (5/5), positive detection
of CrAg (4/5), and positive culture (4/4) (Table 3). Clinically,
patients with positive serum CrAg detection and CM were not
different from those without CM (Table 3). Moreover, 3/5 had
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FIGURE 2 | Venn diagram showing the prevalence of cryptococcal antigen (CrAg) in serum, plasma and urine with the IMMY LFA test in 186 HIV-infected
asymptomatic antiretroviral naïve severely immune depressed patients.
no signs suggestive of meningitis. None of the 29 patients with
isolated positive urine CrAg had CM.
Subsequent Follow-Up and Outcome in
the Study Population
All 5 patients with CM were enrolled in the ACTA trial and
all the others with detectable CrAg by IMMY LFA considered
TABLE 3 | Baseline clinical and laboratory characteristics of patients screened
serum CrAg positive using IMMY LFA and stratified by presence or absence of
cryptococcal meningitis (CM).
Variables With CM
(n = 5)
Without
CM
(n = 18)
p-value
Symptoms
Headache, n (%) 3 (60) 2 (11.8) 0.06
Fever, n (%) 1 (20) 3 (16.7) 0.99
Confusion, n (%) 1 (20) 2 (11.1) 0.54
Photophobia, n (%) 1 (20) 1 (5.6) 0.40
Clinical signs
Neck stiffness, n (%) 2 (40) 0 0.04
Kernig sign, n (%) 2 (40) 0 0.04
Brudzinski sign, n (%) 2 (40) 1 (5.6) 0.10
CSF findings at inclusion
IMMY LFA CrAg positive, n (%) 4 (80) 0 0.001
Indian ink positive, n (%) 5 (100) 0 0.001
Culture positive, n (%) 4 (80) 0 0.001
Glucose in g/L, median (IQR) 0.4
(0.4–0.5)
0.5
(0.40–0.5)
0.08
Proteins in g/L, median (IQR) 0.5
(0.4–0.8)
0.5
(0.3–0.7)
0.72
as asymptomatic cryptococcosis, were prescribed fluconazole.
Median follow-up for the study population was 323 days (IQR:
92–363), not different in serum CrAg positive and negative
patients. Median ART initiation was 3 days (IQR: 1–7) in
CrAg negative patients and 97.5% of all patients started first
line regimen containing tenofovir-lamivudine-efavirenz. Overall
adherence to ART and fluconazole was 100%. At 6 and
12 months, median CD4 cell/ml were, respectively, 208 (IQR:
129–284) and 256 (IQR: 183–315), similar in CrAg positive and
negative patients (p = 0.59). There was no incident case of
cryptococcal meningitis during the total 123.9 person-years-at-
risk (PYAR) follow-up time.
Overall, all-cause mortality was 21% (39/186) at a cumulative
incidence rate of 31.5 per 100 PYAR, occurring within a median
follow-up period of 82 days (IQR: 33–194), 71.8% (28/39) within
the first 3 months of ART. The presence of symptoms of
respiratory and gastrointestinal infections during follow-up was
significantly associated with increased mortality and remained
strongly associated with death after adjusting for other factors
in the multivariate analysis while baseline CrAg positivity was
not (Table 4). Serum CrAg positive patients were less likely to
survive than those who were CrAg negative, p = 0.09 (Figure 3).
In those with baseline confirmed CM, mortality in the first year
was 60% (3/5), with one death attributed to CM (Table 5) on day
4 of treatment.
Impact of the Test and the Specimen
Used for CrAg Screening
With Biosynex CryptoPS, looking at the T1-band results, 5.9% of
patients (11/186) were positive in serum (corresponding to 11/14
of the serum positive with IMMY LFA), 5.9% in urine (11/186,
corresponding to 11/42 of the urine positive with IMMY LFA),
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TABLE 4 | Factors associated with mortality during the first year of antiretroviral (ART) in patients screened for CrAg.
Factors Univariable analysis Multivariable analysis
HR 95% CI p-value aHR 95% CI p-value
Presence of fever 4.2 1.5–12.1 0.007 3.8 1.3–11.2 0.02
Presence of respiratory symptoms 5.2 2.5–10.8 0.001 2.6 1.0–6.3 0.04
Presence of gastrointestinal symptoms 5.4 2.6–11.1 0.001 4.2 1.8–9.7 0.001
Baseline serum CrAg positive (IMMY Diagnostics) 2.2 0.9–5.7 0.09 1.7 0.5–6.2 0.4
FIGURE 3 | Kaplan–Meier survival estimates by serum CrAg status during first year of follow-up.
and 17.4% (4/23) in CSF (4/4 of those positive with IMMY LFA)
(Table 2). No patient was detected with isolated urine CrAg.
Of the 11 patients with the positive T1-band in serum, 10 were
CrAg positive in urine, and 45.5% (5/11) were also T2-band
positive. All 5 patients had CM while none with negative T2-
band had. Of note, 2 of the 5 with CM were T2-band positive
in urine.
Concerning the classification of specimens as positive or
negative, IMMY LFA and Biosynex CryptoPS agreed in 98.4%
of serum and 100% of CSF (Table 2) but with the IMMY test
15.6% (29/186) of patients who had no detectable CrAg in plasma
and serum were CrAg positive in urine (Figure 2). These patients
were thus considered as having false positive detection of CrAg in
urine by the IMMY test. Each POC test had a 98.9% agreement in
classifying plasma and serum specimens from the same patient as
positive or negative (data not shown).
The 186 stored sera tested with EIA, 4.3% (8/186) were
positive. No serum previously categorized as negative
by both POC test was found positive by EIA, including
those with isolated urine CrAg by IMMY LFA. Thus,
considering EIA as reference, IMMY LFA and Biosynex
CryptoPS both had a sensitivity of 100% and respective
specificities of 96.6% (95%CI: 92.8–98.6) and 98.3% (95%CI:
95.2–99.7).
TABLE 5 | Probable causes of death in 39 patients during first year of ART
following CrAg screening.
Probable causes of death CrAg
positive
CrAg
negative
Total deaths,
n (%)
Gastroenteritis 0 12 12 (30.8)
Respiratory/Tuberculosis 0 8 8 (20.5)
Unknown causes 2 6 8 (20.5)
Severe anemia 0 3 3 (7.7)
Kaposi sarcoma 0 2 2 (5.2)
Cryptococcal meningitis 1 0 1 (2.6)
Cerebral toxoplasmosis 1 0 1 (2.6)
Lymphoma 0 1 1 (2.6)
Pulmonary embolism 1 0 1 (2.6)
Severe sepsis 0 1 1 (2.6)
Other meningitis 0 1 1 (2.6)
We then assessed the titres obtained with the three methods.
Median EIA CrAg reciprocal titre in serum was 160 (IQR: 13.5–
718.8), higher in those with microbiologically confirmed CM:
525 (IQR: 160.5–912.5) than in those without: 6.4 (IQR: 1–20.5),
p = 0.003. EIA reciprocal titre threshold of 160 was associated
with the presence of confirmed CM (p = 0.03). Both POC tests
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FIGURE 4 | Scatter plots with highlighted points of agreement of CrAg test in classifying patients with elevated serum CrAg. (A) Enzyme immunoassay (EIA) CrAg
vs. IMMY LFA, (B) EIA CrAg vs. Biosynex T1-band, (C) IMMY LFA vs. Biosynex T1-band, and (D) EIA CrAg vs. Biosynex T2-band.
CrAg titres agreed with EIA titres in stratifying patients with
elevated titres but the T2-band of the Biosynex CryptoPS showed
a stronger pattern of agreement (Figure 4). CrAg titres were also
determined for the 6 serum samples tested negative by EIA, and
positive with LFA IMMY (n = 6) or Biosynex CryptoPS (n = 3).
The reciprocal titres ranged between 10 and 20 for those only
positive with IMMY, and were at 10 and 10, 10 and >20, 80 and
>20 when determined by Biosynex T1-band and IMMY for those
positive with both POC.
Considering serum CrAg positivity as a surrogate marker to
confirmatory CM diagnosis, the IMMY LFA predicted 45.5%
(5/11) of asymptomatic CM while the Biosynex CryptoPS T1-
band predicted 55.5% (5/9) and the T2-band 100% (5/5).
DISCUSSION
In Cameroon where 4.3% (Group Technique Central du Comite
National de Lutte contre le VIH/SIDA, 2015) of adults are HIV-
infected, we found in those presenting with <100 CD4 cells/ml,
that 7.5% were serum CrAg positive using the IMMY LFA
(5.9 and 4.3% using Biosynex CryptoPS and EIA, respectively)
indicating a high risk of CM warranting implementation of
systematic pre-ART CrAg screening in this population (World
Health Organization, 2011). Nevertheless, doing that in a local
context where current application of the HIV “test-and-treat”
strategy (World Health Organization, 2016) does not recommend
baseline pre-ART CD4 T-cell count remains challenging.
Depending on the test used for screening, one out of two to
three patients with positive serum CrAg had asymptomatic CM,
a finding like in other cohorts in the southern part of Africa
(Mfinanga et al., 2015; Longley et al., 2016), suggesting that
systematic LPs should be performed for all asymptomatic CrAg
positive patients as a strategy to timely diagnose CM. Though we
had high LP acceptability within the study, it is not always the
case in routine settings with similar CM risks (Mfinanga et al.,
2015; Longley et al., 2016), thus underlining the need for more
acceptable methods to timely diagnose CM (Jackson and van der
Horst, 2016). This could be achieved by offering LPs only to
those with higher CrAg titres, as high blood titres are associated
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with presence of CM (Longley et al., 2016). Identifying those
with high titres could be done either through serial dilutions
of CrAg positive samples (Rajasingham and Boulware, 2015;
Longley et al., 2016) or through the availability of a CrAg test
capable of directly identifying those with high titres (Jackson
and van der Horst, 2016; Sriruttan et al., 2016). Serial dilution is
expensive, technically demanding, particularly for low-resource
areas, requires a laboratory setting and prolongs diagnostic time.
In our study, the Biosynex CryptoPS semi-quantitative T2-band,
identified patients with high titres and these high titres correlated
with laboratory evidence of asymptomatic CM (Longley et al.,
2016). Such promising performance could be invaluable in
CM diagnostic algorithms especially in settings with low LP
uptake.
During the follow up period, there was no incident case of CM,
a finding comparable to that of a South African cohort (Longley
et al., 2016) where pre-emptive treatment was administered at the
same tapering doses (World Health Organization, 2011). In rural
Uganda, using 800 mg/day preemptively for only 4 weeks (Pac
et al., 2015) yielded similar results within 6 months of follow up.
However, another recent Ugandan cohort described a failure of
fluconazole administered at this recommended pre-emptive dose
in preventing incident CM (HR: 5.4) and death (HR: 3.2) within
6 months of screening and this failure was attributed to baseline
CrAg titres ≥1:160 (Morawski et al., 2016). Here, EIA titres of
1:160 was associated with CM, thereby suggesting that Ugandan
patients at baseline might have had undiagnosed CM for which
fluconazole at 800 mg/day is not suitable. Indeed, this dosage
is not recommended for CM induction treatment (Rothe et al.,
2013) but is more appropriate as pre-emptive therapy. Overall,
these data iterate the importance of considering antigen titre
measurement as a proxy to timely CM diagnosis.
Overall mortality during first year of ART, though high, was
comparable to findings in other cohorts in resource limited
setting (Lawn et al., 2008). We found some evidence of CrAg
positivity and risk of death but not as strong as elsewhere (Liechty
et al., 2007; Jarvis et al., 2009; Pac et al., 2015; Longley et al.,
2016), and this association disappeared upon adjusting with other
factors (Kapoor et al., 2015). Arguably, it could be due to our
relatively smaller sample, but a plausible explanation could also
be our approach of active CM case finding at baseline such
that over time, risks of CM was similar in those found CrAg
positive or negative. Notwithstanding, though mortality in CrAg
negatives in our cohort was still unacceptably high, there were
more early deaths in those screened as CrAg positive but only
one was attributed to CM. CrAg positive patients may have other
poorly understood factors that lead to death due to non-CM
causes; or deaths may have been with undetected cryptococcosis.
The precise cause of death is extremely hard to ascertain in this
patient population.
Our study has some limitations. The number of patients
screened for CrAg was lower than initially planned due to
modifications in local guidelines on diagnosis and treatment of
HIV which reduced the number of potentially eligible patients.
Nevertheless, we believe that our findings may facilitate
management strategies of cryptococcosis in Sub-Saharan African
countries based on excellent performances of both POC tests
used. Considering EIA as the reference standard, both POC had
excellent sensitivity while specificity was slightly better in serum
for Biosynex CryptoPS. Interestingly, though urine screening
provided false positive results with the LFA IMMY as previously
reported (Longley et al., 2016; Brito-Santos et al., 2017), Biosynex
CryptoPS was not associated with false positives in urine.
Acknowledging the constraints around serial dilution for titre
determination and considering that Biosynex CryptoPS T2-band
directly uncovers those with high titres and CM, points out
urgent broad evaluation of this new test as a timely tool for
asymptomatic CM diagnosis.
CONCLUSION
The prevalence of CrAg and asymptomatic CM in Cameroon
is unexpectedly high, thereby suggesting that CM burden may
also be comparably high as described in the Southern part
of Africa. There is urgent need to integrate as part of HIV
comprehensive care package, systematic CrAg screening and
pre-emptive fluconazole therapy as a strategy to reduce HIV-
associated CM morbidity and mortality. The Biosynex CryptoPS
test is comparable to the IMMY LFA as POC CrAg screening test
with apparently less false positive results in urine. The T2-band
of Biosynex CryptoPS, provides a potentially useful surrogate
diagnosis of CM that should prompt lumbar puncture and/or
CM induction antifungal therapy.
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